INVA Stock Balance Sheets

Innoviva Quarterly Balance Sheets Chart

Quarterly

Annual

Goodwill

Account Receivables

Cash and Cash Eq

Account Payables

Deferred Revenue

Inventory

Innoviva Quarterly Balance Sheets Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30

assets
current assets:
cash and cash equivalents	397,532,000	319,090,000	304,964,000	260,630,000	217,003,000	178,357,000	193,513,000	179,997,000	173,025,000	144,049,000	291,049,000	300,789,000	283,580,000	216,802,000	201,525,000	135,115,000	43,265,000	282,890,000	246,487,000	479,193,000	413,147,000	351,981,000	278,096,000	172,946,000	141,952,000	65,151,000	48,615,000	87,226,000	27,138,000	138,417,000	127,634,000	159,808,000	93,194,000	112,945,000	151,778,000	78,746,000	149,579,000	141,186,000	119,575,000	208,052,000	125,275,000	171,892,000	199,243,000	266,070,000	112,235,000	161,096,000	14,310,000	62,736,000	90,658,000	147,874,000	63,101,000	69,721,000	109,923,000	65,589,000	61,098,000	72,918,000	128,966,000	87,610,000	81,283,000	78,860,000	45,545,000	77,152,000	72,388,000	85,730,000	84,898,000	103,522,000	49,787,000	22,359,000	63,879,000	85,499,000	101,411,000	38,004,000
accounts receivable	20,925,000	16,673,000	20,392,000	30,546,000	26,782,000	14,139,000	14,454,000	10,752,000	15,275,000	15,490,000	9,401,000	6,743,000																													3,000	450,000
receivables from collaboration arrangement	67,336,000	61,263,000		60,512,000	67,198,000	61,871,000		57,014,000	65,721,000	60,314,000		65,606,000
inventory	48,996,000	41,479,000	33,725,000	34,236,000	36,664,000	37,437,000	40,737,000	40,515,000	46,846,000	49,653,000	55,897,000	70,807,000																																	5,148,000	4,299,000
prepaid expenses	16,610,000	15,414,000	21,063,000	12,650,000	8,484,000	16,551,000	21,630,000	14,729,000	20,535,000	24,119,000	29,559,000	7,932,000	3,953,000	5,576,000
current portion of isp fund investments	100,198,000	127,790,000	107,532,000
other current assets	181,000	313,000	656,000	2,047,000	2,146,000	2,987,000	4,264,000	1,992,000	2,136,000	2,821,000	2,933,000	2,432,000	1,119,000	1,930,000
total current assets	651,778,000	582,022,000	554,306,000	400,621,000	358,277,000	311,342,000	344,219,000	304,999,000	323,538,000	296,446,000	443,511,000	454,591,000	400,328,000	317,823,000	313,673,000	236,928,000	148,261,000	372,933,000	342,058,000	572,041,000	500,193,000	466,907,000	431,234,000	366,795,000	317,685,000	251,519,000	121,129,000	178,660,000	113,245,000	220,509,000	198,064,000	214,418,000	186,121,000	190,421,000	196,706,000	223,754,000	243,957,000	262,392,000	273,471,000	353,163,000	389,196,000	522,341,000	457,233,000	474,512,000	282,535,000	303,380,000	204,327,000	269,165,000	288,625,000	300,272,000	197,487,000	216,223,000	232,149,000	162,870,000	184,473,000	189,900,000	227,727,000	252,491,000	268,380,000	144,436,000	156,926,000	190,685,000	207,167,000	227,385,000	247,507,000	266,916,000	166,818,000	177,011,000	213,248,000	238,506,000	264,468,000	182,291,000
property and equipment	451,000	483,000	514,000	544,000	427,000	324,000	483,000	361,000	161,000	180,000	170,000	165,000	176,000	191,000	12,000	15,000	19,000	24,000	28,000	33,000	37,000	42,000	33,000	24,000	136,000	148,000	173,000	185,000	197,000	249,000	289,000	328,000	381,000	174,000	193,000	248,000	276,000	303,000	64,000		9,734,000	8,563,000	8,952,000	9,010,000	9,579,000	9,660,000	10,059,000	10,206,000	10,334,000	10,548,000	10,253,000	11,049,000	11,881,000	13,910,000	14,712,000	15,233,000	17,328,000	18,481,000	19,480,000	19,847,000	18,698,000	16,183,000	15,101,000	14,281,000	13,413,000	13,419,000	13,180,000	13,062,000	13,631,000	13,395,000	13,242,000	13,831,000
equity method investments	51,826,000	38,744,000	52,293,000	73,549,000	91,780,000	151,888,000	116,546,000	107,040,000	35,061,000	54,971,000
equity and long-term investments	297,284,000	291,100,000	341,664,000	434,169,000	444,655,000	476,549,000	444,432,000	422,491,000	397,940,000	400,894,000	403,013,000	489,111,000	494,097,000	544,437,000	483,845,000	507,116,000
capitalized fees paid	63,049,000	66,505,000	69,961,000	73,416,000	76,872,000	80,328,000	83,784,000	87,239,000	90,695,000	94,151,000	97,607,000
right-of-use assets	1,759,000	2,110,000	2,453,000	2,789,000	3,118,000	2,269,000	2,536,000	2,828,000	2,719,000	2,973,000	3,265,000	3,679,000	3,545,000	3,794,000
goodwill	17,905,000	17,905,000	17,905,000	17,905,000	17,905,000	17,905,000	17,905,000	17,905,000	14,882,000	27,946,000	26,713,000	15,995,000	5,544,000	5,544,000
intangible assets	195,411,000	201,958,000	208,433,000	210,944,000	217,455,000	223,895,000	230,335,000	236,845,000	243,356,000	248,314,000	252,919,000	258,489,000	105,000,000	105,000,000																									211,646,000	194,880,000	137,477,000	40,000,000
deferred tax assets	12,931,000	12,294,000	12,054,000	14,875,000	11,446,000			4,952,000	6,327,000				23,274,000	22,398,000	17,327,000	28,159,000										187,546,000
other assets	41,178,000	41,269,000	41,477,000	2,800,000	2,982,000	3,112,000	3,267,000	3,444,000	3,562,000	3,893,000	4,299,000	4,620,000	1,157,000	313,000	108,000	136,000	162,000	188,000	214,000	239,000	264,000	288,000	312,000	48,000	37,000	37,000	37,000	37,000	37,000	37,000	37,000	37,000	40,000	58,000	18,000	15,805,000	16,574,000	17,337,000	19,947,000	22,385,000	7,963,000	5,946,000						2,721,000	2,928,000	3,135,000													24,000	100,000	99,000	97,000	100,000	106,000	30,000	31,000	177,000	246,000
total assets	1,333,572,000	1,254,390,000	1,301,060,000	1,231,612,000	1,224,917,000	1,267,612,000	1,243,507,000	1,188,104,000	1,118,241,000	1,129,768,000	1,231,497,000	1,327,712,000	1,137,639,000	1,107,474,000	926,395,000	887,239,000	789,150,000	1,088,290,000	999,570,000	922,256,000	879,619,000	788,011,000	724,826,000	675,953,000	642,307,000	590,114,000	277,693,000	338,692,000	276,745,000	390,972,000	372,023,000	391,872,000	370,542,000	378,109,000	387,829,000	437,631,000	462,086,000	488,699,000	553,713,000	605,610,000	605,034,000	666,016,000	594,704,000	591,519,000	383,943,000	399,422,000	217,727,000	283,325,000	303,120,000	315,108,000	212,580,000	232,449,000	249,930,000	183,472,000	206,085,000	214,792,000	255,262,000	281,390,000	299,515,000	198,623,000	208,008,000	247,659,000	262,424,000	292,350,000	318,897,000	327,334,000	224,835,000	196,988,000	233,801,000	259,196,000	286,022,000	204,974,000
liabilities and stockholders’ equity
current liabilities:
accounts payable	5,382,000	4,700,000	2,132,000	4,170,000	2,039,000	890,000	6,717,000	3,783,000	4,592,000	5,933,000	2,939,000	3,805,000	4,323,000	1,808,000	27,000	89,000	30,000	14,000	66,000	623,000	195,000	122,000	10,000	35,000	1,139,000	144,000	109,000	58,000	66,000	629,000	277,000	2,304,000	528,000	137,000	576,000	154,000	462,000	1,025,000	573,000	1,799,000	5,546,000	5,733,000	4,834,000	3,525,000	4,757,000	4,989,000	5,308,000	3,699,000	2,165,000	2,214,000	1,776,000	1,749,000	1,999,000	1,046,000	1,823,000	1,991,000	2,527,000	3,068,000	4,699,000	5,954,000	7,892,000	8,818,000	16,011,000	8,075,000	10,493,000	11,429,000	8,118,000	7,781,000	8,199,000	9,882,000	5,925,000	3,809,000
accrued personnel-related expenses	4,750,000	3,789,000	7,376,000	5,965,000	4,757,000	3,422,000	7,020,000	5,166,000	5,474,000	4,223,000	8,022,000	6,473,000	3,871,000	1,933,000	619,000	488,000	389,000	652,000	490,000	384,000	291,000	274,000	647,000	509,000	371,000	325,000	1,550,000	695,000	537,000	1,647,000	1,203,000	998,000	1,625,000	1,126,000	913,000	1,392,000	1,003,000	1,063,000	1,203,000	1,023,000	13,829,000	8,362,000	6,001,000	5,128,000	7,714,000			7,123,000	5,154,000		6,398,000	4,692,000	4,133,000	9,482,000	7,958,000	7,552,000	9,116,000	9,898,000	9,783,000	10,597,000	9,263,000	6,154,000	8,316,000	6,562,000	4,423,000	3,950,000	6,041,000	7,828,000	7,092,000	5,149,000	7,615,000	5,793,000
accrued interest payable	3,418,000	833,000	3,422,000	833,000	3,422,000	833,000	3,422,000	833,000	3,422,000	833,000	4,359,000	5,702,000	4,498,000	1,397,000	4,152,000	1,668,000	4,152,000	1,668,000	4,152,000	1,668,000	4,152,000	1,668,000	4,152,000	1,773,000	4,262,000	1,775,000	1,775,000	5,115,000	2,545,000	3,566,000	7,103,000	6,400,000	6,606,000	7,823,000	6,562,000	6,390,000	7,925,000	6,195,000	19,467,000	11,013,000
deferred revenue	3,125,000	1,002,000	1,126,000	717,000	855,000	987,000	1,277,000	1,548,000	3,254,000	2,094,000	2,094,000	2,849,000																		1,551,000	1,772,000	1,993,000	885,000	885,000	885,000	885,000	885,000	885,000	1,082,000	1,082,000	5,247,000								127,393,000	132,409,000	142,246,000	147,946,000	153,647,000	144,946,000	150,495,000	146,792,000	158,510,000	164,509,000	161,421,000	171,544,000	153,733,000	159,038,000	134,383,000	136,555,000	132,660,000	110,467,000	111,251,000	54,601,000	57,607,000	57,978,000	56,339,000	59,079,000
convertible subordinated notes due 2025, net of issuance costs	191,903,000	192,215,000		191,843,000
other accrued liabilities	37,985,000	30,664,000	29,999,000	17,599,000	17,133,000	23,747,000	19,698,000	24,699,000	22,502,000	24,900,000	21,207,000	15,120,000	17,144,000	8,073,000	1,009,000	880,000	800,000	1,470,000	1,402,000	1,223,000	776,000	734,000	562,000	1,012,000	1,386,000	1,258,000	865,000	909,000	918,000	1,157,000	2,460,000	3,183,000	1,729,000	1,392,000	1,687,000	2,457,000	1,789,000	1,686,000	3,773,000	4,834,000	4,792,000	3,093,000	4,703,000	2,678,000	1,835,000	2,077,000	1,974,000				2,650,000	4,335,000	4,003,000	3,986,000	5,470,000	3,754,000	3,072,000	6,483,000	4,104,000	2,795,000	3,431,000	3,519,000	2,314,000	2,000,000	1,653,000	2,208,000	1,997,000	1,966,000	2,213,000	2,094,000	2,338,000	4,573,000
total current liabilities	246,563,000	234,745,000	236,083,000	223,750,000	28,206,000	29,879,000	38,134,000	36,183,000	39,398,000	38,137,000	134,968,000	163,884,000	125,908,000	109,227,000	5,807,000	3,125,000	5,371,000	3,804,000	6,110,000	3,898,000	5,414,000	2,798,000	5,371,000	3,329,000	7,475,000	3,810,000	4,299,000	6,777,000	4,066,000	32,884,000	27,109,000	20,473,000	14,924,000	14,629,000	10,623,000	11,278,000	12,214,000	10,980,000	36,098,000	49,994,000	44,144,000	38,661,000	38,646,000	29,464,000	27,090,000	25,776,000	25,575,000	39,814,000	35,191,000	33,419,000	36,381,000	36,004,000	35,576,000	39,341,000	40,369,000	37,416,000	43,705,000	50,172,000	49,720,000	57,136,000	59,802,000	62,886,000	59,609,000	54,801,000	54,047,000	53,112,000	48,173,000	40,427,000	38,330,000	36,013,000	35,037,000	33,311,000
long-term debt, net of discount and issuance costs	257,019,000	256,670,000	256,316,000	255,972,000	447,282,000	446,759,000	446,234,000	445,718,000	445,201,000	444,692,000	444,180,000	443,679,000	443,178,000	442,731,000	394,653,000	392,295,000	389,989,000	387,728,000	385,517,000	383,350,000	381,230,000	379,152,000	377,120,000	388,644,000	386,675,000	384,744,000
other long-term liabilities	60,021,000	62,009,000	64,275,000	71,449,000	72,065,000	71,686,000	71,870,000	68,690,000	68,584,000	70,133,000	70,918,000	78,421,000				14,000					163,000	192,000		217,000	298,000	379,000	668,000	752,000	835,000	1,049,000	1,159,000	1,267,000	1,598,000	1,639,000	1,784,000	1,847,000	1,748,000	1,947,000	1,530,000	1,300,000													314,000	466,000	543,000	620,000	3,670,000	3,655,000
income tax payable, long-term	55,148,000	54,061,000	53,227,000	11,899,000	11,849,000	11,800,000	11,751,000	10,020,000	9,971,000	9,921,000	9,872,000
commitments and contingencies
stockholders’ equity:
preferred stock: 0.01 par value, 230 shares authorized, no shares issued and outstanding
common stock: 0.01 par value, 200,000 shares authorized, 63,011 and 62,665 issued and outstanding as of june 30, 2025 and december 31, 2024, respectively	630,000
additional paid-in capital	698,884,000	694,658,000	692,329,000	690,045,000	688,231,000	1,085,539,000	1,093,340,000	1,107,398,000	1,117,029,000	1,124,709,000	1,163,836,000	1,171,096,000	1,183,667,000	1,182,912,000	1,264,024,000	1,262,438,000	1,261,845,000	1,261,326,000	1,260,900,000	1,260,447,000	1,260,017,000	1,259,464,000	1,258,859,000	1,258,370,000	1,257,799,000	1,257,125,000	1,258,350,000	1,259,443,000	1,257,880,000	1,336,358,000	1,286,340,000	1,284,031,000	1,292,655,000	1,312,434,000	1,328,155,000	1,375,805,000	1,400,253,000	1,426,297,000	1,466,911,000	1,444,105,000	1,834,862,000	1,784,016,000	1,492,945,000	1,462,288,000	1,475,371,000	1,456,882,000	1,236,641,000	1,218,934,000	1,210,006,000	1,194,620,000	1,039,357,000	1,033,427,000	1,025,548,000	918,634,000	912,070,000	905,453,000	889,844,000	882,369,000	876,007,000	863,177,000	855,951,000	846,924,000	840,498,000	833,452,000	827,704,000	818,160,000	676,299,000	674,109,000	673,969,000	671,144,000	669,698,000	562,355,000
retained earnings	15,307,000					11,343,000
total stockholders’ equity	714,821,000	646,905,000	691,159,000	668,542,000	665,515,000	703,681,000	674,955,000	627,493,000	555,087,000	561,493,000	565,788,000	641,368,000	565,462,000	552,217,000	525,935,000	491,805,000	393,745,000	696,681,000	607,837,000	534,872,000	492,812,000	405,869,000	342,116,000	283,763,000	246,702,000	199,943,000															263,252,000	330,049,000	85,647,000	91,511,000	173,288,000	189,256,000	6,131,000															20,344,000	63,310,000	94,034,000	125,607,000	157,520,000	59,584,000	98,177,000	133,958,000	161,078,000	190,367,000	108,098,000
total liabilities and stockholders’ equity	1,333,572,000	1,254,390,000	1,301,060,000	1,231,612,000	1,224,917,000	1,267,612,000	1,243,507,000	1,188,104,000	1,118,241,000	1,129,768,000	1,231,497,000	1,327,712,000	1,137,639,000	1,107,474,000	926,395,000	887,239,000	789,150,000	1,088,290,000	999,570,000	922,256,000	879,619,000	788,011,000	724,826,000	675,953,000	642,307,000	590,114,000														605,610,000	605,034,000	666,016,000	594,704,000	591,519,000	383,943,000	399,422,000	217,727,000										255,262,000	281,390,000	299,515,000	198,623,000	208,008,000	247,659,000	262,424,000	292,350,000	318,897,000	327,334,000	224,835,000	196,988,000	233,801,000	259,196,000
income tax payable		1,542,000		2,623,000				154,000	154,000	154,000	154,000	33,804,000
common stock: 0.01 par value, 200,000 shares authorized, 62,771 and 62,665 issued and outstanding as of march 31, 2025 and december 31, 2024, respectively		628,000
accumulated deficit		-48,381,000	-1,797,000	-22,129,000	-23,342,000		-25,189,000	-86,720,000	-168,766,000	-170,046,000	-204,911,000	-136,597,000	-402,198,000	-403,137,000	-456,148,000	-466,493,000	-538,931,000	-627,879,000	-722,002,000	-775,905,000	-804,123,000	-880,967,000	-946,404,000	-992,353,000	-1,032,162,000
receivable from collaboration arrangements			65,974,000																																									2,217,000
convertible notes, due 2025, net of issuance costs			192,028,000
deferred tax liabilities						3,807,000	563,000			5,392,000	5,771,000	360,000
common stock: 0.01 par value, 200,000 shares authorized, 62,665 and 63,307 issued and outstanding as of december 31, 2024 and 2023 respectively			627,000
treasury stock						-393,829,000	-393,829,000	-393,829,000	-393,829,000	-393,829,000	-393,829,000	-393,829,000	-393,829,000	-393,829,000	-393,829,000	-393,829,000
common stock: 0.01 par value, 200,000 shares authorized, 62,601 and 63,307 issued and outstanding as of september 30, 2024 and december 31, 2023, respectively				626,000
common stock: 0.01 par value, 200,000 shares authorized, 62,562 and 63,307 issued and outstanding as of june 30, 2024 and december 31, 2023, respectively					626,000
common stock: 0.01 par value, 200,000 shares authorized, 62,797 and 63,307 issued and outstanding as of march 31, 2024 and december 31, 2023, respectively						628,000
receivables from collaboration arrangements							69,621,000				54,672,000
convertible subordinated notes due 2023, net of issuance costs											96,193,000	96,131,000	96,072,000	96,016,000
common stock: 0.01 par value, 200,000 shares authorized, 63,307 and 69,188 issued and outstanding as of december 31, 2023 and december 31, 2022 respectively							633,000
common stock: 0.01 par value, 200,000 shares authorized, 64,384 and 69,188 issued and outstanding as of september 30, 2023 and december 31, 2022, respectively								644,000
common stock: 0.01 par value, 200,000 shares authorized, 65,225 and 69,188 issued and outstanding as of june 30, 2023 and december 31, 2022, respectively									653,000
common stock: 0.01 par value, 200,000 shares authorized, 65,824 and 69,188 issued and outstanding as of march 31, 2023 and december 31, 2022, respectively										659,000
common stock: 0.01 par value, 200,000 shares authorized, 69,188 and 69,566 issued and outstanding as of december 31, 2022 and december 31, 2021 respectively											692,000
total innoviva stockholders’ equity											565,788,000	641,368,000	388,337,000	386,642,000	414,743,000	402,811,000										188,245,000
noncontrolling interests
short-term marketable securities												282,000									3,999,000	31,970,000	72,749,000	124,255,000	107,711,000	127,027,000	6,865,000	20,316,000	29,322,000	29,775,000	7,992,000	10,003,000	55,772,000	40,921,000	16,414,000	127,446,000	79,684,000	109,954,000	143,536,000
capitalized fees paid to a related party												101,062,000	104,518,000	107,974,000	111,430,000	114,885,000	118,341,000	121,797,000	125,253,000	128,708,000	132,164,000	135,620,000	139,076,000	142,531,000	145,987,000	149,443,000	156,354,000	159,810,000	163,266,000	170,177,000	173,633,000	177,089,000	184,000,000	187,456,000	190,912,000	197,824,000	201,279,000
common stock: 0.01 par value, 200,000 shares authorized, 69,776 and 69,566 issued and outstanding as of september 30, 2022 and december 31, 2021 respectively												698,000
noncontrolling interest													177,125,000	165,575,000	111,192,000	88,994,000										11,698,000	3,081,000	1,992,000	811,000
related party receivables from collaborative arrangements													111,676,000	93,515,000	110,711,000	101,271,000	104,262,000	88,974,000	93,931,000	92,150,000	82,402,000	82,134,000	79,427,000	69,211,000	67,563,000	58,639,000	65,136,000	70,542,000	55,835,000	51,878,000	61,796,000	43,727,000	36,621,000	35,817,000	27,539,000	16,947,000	13,997,000	10,239,000
lease liabilities, long-term													3,091,000	3,299,000
common stock: 0.01 par value, 200,000 shares authorized, 69,706 and 69,566 issued and outstanding as of june 30, 2022 and december 31, 2021 respectively													697,000
common stock: 0.01 par value, 200,000 shares authorized, 69,594 and 69,566 issued and outstanding as of march 31, 2022 and december 31, 2021 respectively														696,000
prepaid expenses and other current assets															1,437,000	542,000	734,000	1,069,000	1,640,000	698,000	645,000	822,000	962,000	383,000	459,000	702,000	513,000	576,000	950,000	439,000	642,000	880,000	534,000	738,000	975,000	615,000	697,000	1,013,000	748,000	982,000	6,391,000	4,071,000	3,609,000	5,190,000				3,848,000	4,506,000	5,751,000
common stock: 0.01 par value, 200,000 shares authorized, 69,566 and 101,392 issued and outstanding as of december 31, 2021 and december 31, 2020 respectively															696,000
common stock: 0.01 par value, 200,000 shares authorized, 69,492 and 101,392 issued and outstanding as of september 30, 2021 and december 31, 2020 respectively																695,000

common stock: 0.01 par value, 200,000 shares authorized, 69,495 and 101,392 issued and outstanding as of june 30, 2021 and december 31, 2020, respectively																	695,000
liabilities and stockholders' equity
common stock: 0.01 par value, 200,000 shares authorized, 101,408 and 101,392 issued and outstanding as of march 31, 2021 and december 31, 2020, respectively																		1,014,000
equity and other long-term investments
common stock: 0.01 par value, 200,000 shares authorized, 101,392 and 101,288 issued and outstanding as of december 31, 2020 and december 31, 2019, respectively																			1,014,000
accumulated other comprehensive income																					-2,000	33,000	27,000	25,000	33,000	10,000							8,000	6,000		11,000				3,706,000	171,000	202,000		92,000	116,000			16,000		28,000	77,000			61,000	198,000	327,000			362,000	81,000	34,000	81,000	26,000
equity investments
common stock: 0.01 par value, 200,000 shares authorized, 101,391 and 101,288 issued and outstanding as of september 30, 2020 and december 31, 2019, respectively																				1,014,000
common stock: 0.01 par value, 200,000 shares authorized, 101,392 and 101,288 issued and outstanding as of june 30, 2020 and december 31, 2019, respectively																					1,015,000
common stock: 0.01 par value, 200,000 shares authorized, 101,320 and 101,288 issued and outstanding as of march 31, 2020 and december 31, 2019, respectively																						1,013,000
common stock: 0.01 par value, 200,000 shares authorized, 101,288 and 101,098 issued and outstanding as of december 31, 2019 and 2018, respectively																							1,013,000
common stock: 0.01 par value, 200,000 shares authorized, 101,279 and 101,098 issued and outstanding as of september 30, 2019 and december 31, 2018, respectively																								1,013,000
operating lease right-of-use asset																										1,421,000
operating lease liability, current portion																										308,000
operating lease liability, net of current portion																										1,238,000
common stock: 0.01 par value, 200,000 shares authorized, 101,272 and 101,098 issued and outstanding as of june 30, 2019 and december 31, 2018, respectively																									1,013,000
common stock: 0.01 par value, 200,000 shares authorized, 101,183 and 101,098 issued and outstanding as of march 31, 2019 and december 31, 2018, respectively																										1,012,000
liabilities and stockholders’ deficit
current portion of long-term debt																														25,000,000
long-term debt, net of current portion, discount and issuance costs																											381,002,000	486,527,000	484,591,000	578,449,000
stockholders’ deficit:
common stock: 0.01 par value, 200,000 shares authorized, 101,189 and 102,046 shares issued as of september 30, 2018 and december 31, 2017, respectively																											1,011,000
accumulated other comprehensive loss
total innoviva stockholders’ deficit
total stockholders’ deficit
total liabilities and stockholders’ deficit																											277,693,000	338,692,000	276,745,000	390,972,000	372,023,000	391,872,000	370,542,000	378,109,000	387,829,000	437,631,000	462,086,000	488,699,000
royalty revenue from a related party, net of amortization of capitalized fees paid to a related party of 3,456 in the three months ended september 30, 2018 and 2017 and 10,368 in the nine months ended september 30, 2018 and 2017																											61,680,000
revenue from collaborative arrangements from a related party																														221,000	221,000	221,000	221,000	221,000	221,000	221,000	221,000	222,000
total net revenue																											61,680,000	67,086,000	52,380,000	48,643,000	58,562,000	40,492,000	33,309,000	32,472,000	24,176,000	13,562,000	10,655,000	6,896,000
operating expenses:
research and development																														311,000	348,000	354,000	286,000	370,000	392,000	547,000	638,000	712,000										27,837,000	22,798,000	20,464,000	18,537,000	18,705,000	20,351,000	19,541,000	20,020,000	19,557,000
general and administrative																											4,019,000	4,411,000	8,985,000	8,310,000	10,384,000	10,795,000	5,105,000	6,225,000	6,252,000	4,581,000	4,909,000	5,439,000										7,796,000	7,248,000	7,169,000	6,610,000	6,991,000	6,476,000	7,061,000	6,796,000	7,052,000
general and administrative - related party																													2,700,000
total operating expenses																											4,019,000	4,411,000	11,685,000	8,621,000	10,732,000	11,149,000	5,391,000	6,595,000	6,644,000	5,128,000	5,547,000	6,151,000										35,633,000	30,046,000	27,633,000	25,147,000	25,696,000	26,827,000	26,596,000	26,846,000	27,892,000
income from operations																											57,661,000	62,675,000	40,695,000	40,022,000	47,830,000	29,343,000	27,918,000	25,877,000	17,532,000	8,434,000	5,108,000	745,000
other income																												39,000				47,000	56,000	1,719,000				1,178,000
interest income																											370,000	380,000	391,000	376,000	306,000	236,000	162,000	157,000	92,000	90,000	85,000	116,000										81,000	118,000	145,000
interest expense
net income																											50,167,000	56,616,000	30,330,000	23,767,000	35,146,000	16,845,000	15,033,000	14,597,000	4,435,000	-4,584,000	-7,810,000	-10,667,000										-30,626,000	-25,045,000	-22,667,000	-21,222,000	-20,806,000	-22,536,000	-22,183,000	-21,692,000	-19,217,000
net income attributable to noncontrolling interest																											3,078,000	1,990,000	749,000
net income attributable to innoviva stockholders																											47,089,000	54,626,000	29,581,000
basic net income per share attributable to innoviva stockholders																											470	540	290
diluted net income per share attributable to innoviva stockholders																											430	490	270
shares used to compute innoviva basic and diluted net income per share:
shares used to compute basic net income per share																											100,936,000	100,873,000	100,604,000	106,841,000	107,614,000	107,487,000	109,282,000	111,359,000	112,482,000
shares used to compute diluted net income per share																											113,363,000	113,399,000	113,566,000	119,796,000	120,463,000	120,336,000	121,993,000	124,316,000	113,178,000
common stock: 0.01 par value, 200,000 shares authorized, 101,657 and 102,046 shares issued as of june 30, 2018 and december 31, 2017, respectively																												1,015,000
royalty revenue from a related party, net of amortization of capitalized fees paid to a related party of 3,456 in the three months ended june 30, 2018 and 2017 and 6,912 in the six months ended june 30, 2018 and 2017																												67,086,000
common stock: 0.01 par value, 200,000 shares authorized, 101,475 and 102,046 shares issued as of march 31, 2018 and december 31, 2017, respectively																													1,014,000
royalty revenue from a related party, net of amortization of capitalized fees paid to a related party of 3,456 in the three months ended march 31, 2018 and 2017																													52,380,000
deferred revenue, current																														885,000	885,000	885,000									8,814,000	9,601,000	8,974,000	9,881,000	4,945,000	5,771,000	5,771,000	20,887,000	20,553,000	21,238,000
common stock: 0.01 par value, 200,000 shares authorized, 108,152 and 108,585 shares issued as of september 30, 2017 and december 31, 2016, respectively																														1,080,000
royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 for the three months ended september 30, 2017 and 2016 and 10,368 for the nine months ended september 30, 2017 and 2016																														48,422,000
basic net income per share																														220	330	160
diluted net income per share																														210	300	150
shares used to compute basic and diluted net income per share:
non-recourse notes, due 2029, current																															15,181,000	6,703,000	3,551,000	3,266,000
convertible subordinated notes, due 2023, net of issuance costs																															237,858,000	237,724,000	241,535,000	241,408,000
non-recourse notes, due 2029, net of issuance costs																															400,854,000	464,601,000	477,914,000	480,879,000
common stock: 0.01 par value, 200,000 shares authorized, 109,510 and 108,585 shares issued as of june 30, 2017 and december 31, 2016, respectively																															1,094,000
royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 for the three months ended june 30, 2017 and 2016 and 6,912 for the six months ended june 30, 2017 and 2016																															58,341,000
common stock: 0.01 par value, 200,000 shares authorized, 109,348 and 108,585 shares issued as of march 31, 2017 and december 31, 2016, respectively																																1,093,000
royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 for the three months ended march 31, 2017 and 2016																																40,271,000
common stock: 0.01 par value, 200,000 shares authorized, 109,690 and 114,933 shares issued as of september 30, 2016 and december 31, 2015, respectively																																	1,098,000
royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 and 3,455 for the three months ended september 30, 2016 and 2015 and 10,368 and 10,367 for the nine months ended september 30, 2016 and 2015																																	33,088,000
basic net income per share:																																	140
diluted net income per share:																																	130
cash dividends declared per common share																																						250
common stock: 0.01 par value, 200,000 shares authorized, 111,617 and 114,933 shares issued as of june 30, 2016 and december 31, 2015, respectively																																		1,116,000
royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 and 3,456 for the three months ended june 30, 2016 and 2015 and 6,912 and 6,912 for the six months ended june 30, 2016 and 2015																																		32,251,000
basic and diluted net income per share																																		130	40	-40	-70											-370	-310	-280	-290	-280	-350	-350	-350	-310
cash dividend declared per common share																																				250	250
convertible subordinated notes, due 2023																																			251,124,000	255,109,000	255,109,000	255,109,000
non-recourse notes, due 2029																																			483,389,000	488,976,000	483,363,000	476,954,000
common stock: 0.01 par value, 200,000 shares authorized, 113,146 and 114,933 shares issued as of march 31, 2016 and december 31, 2015, respectively																																			1,132,000
royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 for the three months ended march 31, 2016 and 2015																																			23,955,000
marketable securities																																						3,932,000	47,752,000	34,349,000	59,831,000	88,333,000	90,314,000	99,342,000			185,854,000	202,433,000	193,229,000	145,945,000	129,367,000	140,972,000	115,525,000	88,640,000	114,585,000	105,958,000	89,871,000	144,737,000	176,384,000	58,678,000	105,107,000	107,482,000	128,692,000	137,525,000	157,543,000	155,073,000	112,138,000	149,964,000	138,499,000	146,333,000	155,730,000	136,334,000
payable to theravance biopharma, inc.																																					150,000	126,000		15,243,000
deferred rent																																				100,000	102,000	89,000	54,000	13,000	4,891,000	4,658,000	4,698,000	4,872,000	5,275,000	5,477,000	5,678,000				2,488,000	1,782,000	709,000	1,121,000	1,280,000	1,440,000	1,680,000	1,801,000	1,921,000	2,085,000	2,149,000	2,225,000	2,298,000	2,572,000	2,573,000	2,573,000	2,538,000	2,669,000	2,569,000	2,534,000	2,500,000	2,336,000
common stock: 0.01 par value, 200,000 shares authorized, 117,575 and 116,445 shares issued as of september 30, 2015 and december 31, 2014, respectively																																				1,176,000
royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,455 and 3,233 for the three months ended september 30, 2015 and 2014 and 10,367 and 7,611 for the nine months ended september 30, 2015 and 2014																																				13,341,000
income from continuing operations before income taxes
income tax benefit
income from continuing operations, net of tax
income from discontinued operations
basic and diluted net income per share:
continuing operations, net of tax																																				-40	-70
discontinued operations
shares used to compute basic and diluted net income per share																																				115,787,000	115,329,000	114,658,000
common stock: 0.01 par value, 200,000 shares authorized, 117,174 and 116,445 shares issued as of june 30, 2015 and december 31, 2014, respectively																																					1,172,000
royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 and 2,598 for the three months ended june 30, 2015 and 2014 and 6,912 and 4,378 for the six months ended june 30, 2015 and 2014																																					10,434,000
income tax expense
captialized fees paid to a related party																																						204,735,000
common stock: 0.01 par value, 200,000 shares authorized, 116,920 and 116,445 shares issued as of march 31, 2015 and december 31, 2014, respectively																																						1,169,000
royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 and 1,780 for the three months ended march 31, 2015 and 2014																																						6,674,000
income from continuing operations
continuing operations																																						-90
restricted cash																																							5,600,000	14,232,000	833,000	833,000	833,000	833,000	833,000	833,000	893,000	893,000	893,000	893,000	893,000	893,000	1,310,000	1,310,000	1,310,000	3,810,000	3,810,000	3,810,000	3,810,000
receivables from collaborative arrangements																																							4,012,000	3,473,000	865,000	2,489,000	2,233,000
inventories																																									11,014,000	9,038,000	8,240,000	8,049,000
liabilities and stockholders’ (deficit) equity
payable to a related party																																							10,000,000	15,000,000
accrued clinical and development expenses																																									9,890,000	10,599,000	9,222,000	6,054,000	6,761,000	4,898,000	6,547,000	5,075,000	2,850,000	2,759,000	2,553,000	2,231,000	2,449,000	2,585,000	2,917,000	2,775,000	4,881,000	6,618,000	8,440,000	14,952,000	17,901,000	23,083,000	13,608,000	15,593,000	15,353,000	17,043,000	13,779,000	9,769,000	7,648,000	5,716,000	5,579,000	4,907,000
convertible subordinated notes																																							255,109,000	287,500,000	287,500,000	287,500,000	459,960,000	460,000,000	172,500,000	172,500,000	172,500,000	172,500,000	172,500,000	172,500,000	172,500,000	172,500,000	172,500,000	172,500,000	172,500,000	172,500,000	172,500,000	172,500,000	172,500,000
non-recourse notes payable, due 2029																																							450,000,000	450,000,000
stockholders’ (deficit) equity:
common stock																																							1,154,000	1,133,000	1,125,000	1,105,000	1,008,000	993,000	979,000	969,000	865,000	851,000	754,000	722,000	645,000	642,000	637,000	542,000	538,000	533,000	523,000	520,000	516,000	514,000	512,000	508,000	507,000	505,000	503,000	500,000	444,000	442,000	440,000	437,000	435,000	364,000
total stockholders’ (deficit) equity
total liabilities and stockholders’ (deficit) equity																																							553,713,000
short-term investments																																								126,424,000	245,648,000	334,261,000	243,768,000	192,986,000	161,209,000	134,393,000
stockholders’ equity
accrued interest on convertible subordinated notes																																									1,273,000	1,273,000	4,912,000	2,198,000	1,078,000	2,372,000	1,078,000	1,078,000	2,372,000	1,078,000
notes receivable																																										140,000						85,000	200,000	370,000	532,000	434,000	448,000	224,000	227,000	179,000	311,000	503,000	583,000	437,000	365,000	17,000	1,118,000	2,924,000	2,973,000	2,883,000	2,496,000	2,592,000	2,609,000	2,542,000	2,989,000	2,994,000
deferred revenue, non-current																																										5,148,000	5,753,000	5,672,000	5,790,000	6,413,000	7,843,000	124,435,000
notes receivable, current																																											140,000			100,000	200,000
intangible asset																																											30,000,000
other assets, non-current																																											7,372,000	7,682,000	1,894,000	2,101,000	2,308,000
notes receivable, non-current																																												140,000	140,000	240,000	140,000
receivable from related party																																													71,000	94,000	63,000				184,000	33,000	16,000	144,000	248,000	269,000	231,000	10,030,000	167,000	98,000	228,000	229,000	608,000	272,000	417,000	4,032,000	990,000	953,000	6,287,000	1,548,000	2,124,000	1,527,000
note receivable, current																																													100,000
prepaid and other current assets																																													3,772,000	3,398,000	3,900,000				4,303,000	5,063,000	6,237,000	8,273,000	8,315,000	10,576,000	8,348,000	9,611,000	9,963,000	6,363,000	5,681,000	5,805,000	4,361,000	3,858,000	4,471,000	4,051,000	3,903,000	3,735,000	4,583,000	5,126,000	5,203,000	6,426,000
long-term marketable securities																																													88,962,000	83,208,000
note payable and capital lease
accrued personnel related expenses																																														5,669,000	4,884,000
note payable and capital lease, current																																															13,000	109,000	162,000	200,000
accounts receivable from related party																																																63,000	32,000	332,000
liabilities and stockholders’ net capital deficiency
other current liabilities																																																1,843,000	1,935,000	1,724,000
deferred rent, non-current																																																5,728,000	5,518,000	4,586,000
note payable and capital lease, non-current
stockholders’ net capital deficiency:
class a common stock																																																	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	94,000	90,000
total stockholders’ net capital deficiency
total liabilities and stockholders’ net capital deficiency																																																283,325,000	303,120,000	315,108,000	212,580,000	232,449,000	249,930,000	183,472,000	206,085,000	214,792,000
revenue																																																6,431,000	6,389,000	6,331,000	5,302,000	6,264,000	5,714,000	5,515,000	5,493,000	9,544,000
shares used in computing basic and diluted net income per share																																																82,490,000	81,811,000	80,854,000			64,921,000	63,236,000
accrued personnel -related expenses																																																		4,206,000
notes payable and capital lease, non-current																																																		13,000
other long-term assets																																																			3,547,000	3,754,000	3,960,000	4,374,000	4,580,000	4,787,000	5,201,000	5,407,000
current portion of note payable and capital lease																																																			202,000	195,000	191,000	181,000	175,000
current portion of deferred revenue																																																			22,802,000	22,802,000	22,801,000	22,061,000	22,026,000	21,223,000	23,996,000	23,996,000	22,589,000	22,740,000	21,221,000	21,221,000	19,273,000	22,032,000	21,452,000	17,480,000	16,994,000	12,021,000	12,021,000	11,563,000	10,959,000	10,959,000
notes payable and capital lease																																																			109,000	175,000	213,000	311,000	359,000
restructuring charges																																																							30,000	1,283,000
interest and other income																																																			136,000	134,000	94,000	413,000	1,172,000	647,000
shares used in computing net income per share																																																			73,726,000	73,282,000			62,842,000	62,288,000
preferred stock, 0.01 par value, 230 shares authorized, no shares issued and outstanding
current portion of note payable																																																								121,000	113,000	109,000	105,000
notes payable																																																								286,000	349,000	379,000	408,000	462,000	488,000	513,000	538,000	570,000	589,000	607,000	631,000	656,000	669,000	688,000	706,000	723,000
other long term assets																																																											5,614,000
other long term liabilities																																																											4,139,000	8,281,000	7,632,000	2,653,000	2,286,000	3,818,000	3,421,000	3,055,000	2,658,000
restricted cash and cash equivalents																																																												3,810,000	3,830,000	3,830,000	3,860,000	3,860,000	3,860,000	3,860,000	3,860,000	3,860,000	3,860,000	4,194,000	4,537,000	4,923,000
current portion of notes payable																																																												98,000	94,000	91,000	87,000	75,000	75,000	75,000	75,000	67,000	70,000	167,000	262,000	354,000
notes receivable from stockholders
deferred sublease costs																																																																			297,000	357,000	416,000	476,000	545,000	614,000
current portion of capital lease obligations																																																																464,000	598,000	927,000	1,169,000	995,000	1,087,000	1,442,000	2,359,000	2,916,000
deferred stock-based compensation
preferred stock, 0.01 par value; 230 shares authorized, no shares issued and outstanding
deferred sublease cost																																																																	178,000	238,000
notes receivable from related parties																																																																					7,000	52,000	64,000	75,000
capital lease obligations																																																																				458,000	668,000	905,000	1,073,000	1,427,000
liabilities, convertible preferred stock and stockholders’ equity
convertible preferred stock, 0.01 par value; no shares authorized, issued or outstanding at december 31, 2004; 50,000 shares authorized and 47,644 shares issued and outstanding at december 31, 2003, aggregate liquidation preference of 374,468 at december 31, 2003.
total liabilities, convertible preferred stock, and stockholders’ equity																																																																							286,022,000	204,974,000
commitments
convertible preferred stock, 0.01 par value; 50,000 shares authorized; no shares outstanding at september 30, 2004;47,644 shares issued and outstanding at december 31, 2003, aggregate liquidation preference of 374,468 at december 31, 2003.
preferred stock, 0.01 par value, 5,000 shares authorized, no shares issued and outstanding

We provide you with 20 years of balance sheets for Innoviva stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Innoviva. Explore the full financial landscape of Innoviva stock with our expertly curated balance sheets.

The information provided in this report about Innoviva stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.